To: Jenna who wrote (25355 ) 2/22/1999 9:34:00 AM From: Jenna Respond to of 120523
GELX.. keep an eye on that one.<<NDB>>brokers hot again. NOBE, reporting today looks hot. Watch the retailers.. MCSC gapped up. TEVIY reported looking okay, don't chase it, it will come. CMD still on fire. Subscribers...#5 on today's calendar looks like it might move up. The New Newsletter is on the newsletter menu and the watch list is on the Watch List section. Watch HD, our earnings play.. looks good.Another good gap up for TRVL and GVA.. Teva Pharmaceutical Industries Ltd. Reports 1998 Year End and Fourth Quarter Financial Results Fourth Quarter Normalized Net Income Increased by 39%, Excluding One-time Charges JERUSALEM, Israel--(BUSINESS WIRE)--Feb. 22, 1999-- Declares Regular Quarterly Cash Dividend Teva Pharmaceutical Industries Ltd., (Nasdaq: TEVIY - news) today reported financial results for the year and fourth quarter ended December 31, 1998. For the year ended December 31, 1998, total consolidated sales amounted to $1.116 billion, as compared to $1.117 billion in 1997. On a normalized basis, (factoring out a number of restructuring and other special charges in both 1998 and 1997 as discussed below), net income in 1998 amounted to $97.3 million, or $1.60 per ADR, as compared to $122.5 million, or $1.98 per ADR, in 1997. For the fourth quarter ended December 31, 1998, total consolidated sales amounted to $296.9 million, an increase of 2% over the comparable 1997 quarter. Net income on a normalized basis for the two comparative quarterly periods, amounted to $29.6 million for the fourth quarter of 1998, as compared to $21.2 million, an increase of 39%. Earnings per ADR on a normalized basis for the fourth quarter of 1998 were $0.51, as compared to $0.34 in the 1997 period. Reported net income for the year ended 1998, amounted to $68.8 million, or $1.15 per ADR, compared to $101.5 million, or $1.65 per ADR, in 1997 (including non-recurring items in both periods). Reported net income for the quarter amounted to $1.4 million, or $0.06 per ADR, as compared to $0.2 million, or $0.01 per ADR, in 1997 (including non-recurring items in both periods).